Technology

Spurred on by COVID-19 and companies’ evolving digital maturity, AI looks set to gain a real foothold in pharma’s promotional activities.

Providing ultimate value to stakeholders remains key in new style of development.

Scott Swain details the most common roadblocks that pharma companies experience when incorporating real-world data (RWD) in regulatory submissions and looks at how they can be addressed.

As emerging technologies are identified, C-suites need to determine how they might be pragmatically deployed as solutions to address their pain points, says IBM‘s Dr. Bernard S. Meyerson.

The constantly evolving world of data is forcing pharma companies to implement new strategies for improved structure.

As the pressure on teams reviewing promotional content has increases, both in terms of volumes of content and complexity, Sameer Lal discusses the need for a near-term strategies using artificial intelligence (AI) and machine learning (ML) to decongest bottlenecks of the manual review process.

2021‘s Pharmaceutical Industry Network Group (PING) conference focused on the UK’s COVID-19 response and how it can continue as a leader in science innovation and collaboration, including opportunities through use of health and genomic data.

Meeting demands of the new marketplace.

In order to address data literacy gaps amongst reps and managers, sales trainers are increasingly turning to computer-based business simulation games, writes Jeremy Lovelace.

Critics proclaim that recent RWD guidance issued by FDA still has a good number of gaps to fill and may take some time to accomplish.

Practices to ensure accuracy in selected datasets.

The MIT Institute for Work and Employment Research’s Dr. Thomas Kochan offers three key insights on engaging with AI and other digital solutions as they continue to transform the working environment.

Comprehensive dosage monitoring of topical treatments for mild to moderate psoriasis.

According to new research, quality has overtaken cost as a priority in plans for automating adverse event reporting. John Price reveals the drivers and barriers to change.

Healthcare professionals (HCPs) shouldn’t miss out on critical information while their focus is on their patients, which is why messages on professional platforms are an essential resource to improve a patient’s health results, writes Gareth Shaw.

How can pharma create solutions that are effective, can provide long-term value, and will actually be adopted by HCPs and patients?

Industry leaders share perspectives on moving the life sciences industry forward.

Traditionally difficult in pharma, data science recruitment witnessed a sharp drop-off at the beginning of the pandemic, but interest has since bounced back to unexpected levels.

Chris Doerr, Senior Vice President, Global Generic Sourcing, AmerisourceBergen, talks about the importance of companies taking an honest view of their current-state capabilities when embarking on the digital transformation journey.

Creating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.

Clay Hausmann describes how Almirall is weeding out uncertainty to sow the seeds of data-driven digital transformation.

Unconventional collaborations between biopharma and tech are starting to take off.

While there is broad agreement that the Chief Data Officer plays a critical part in pharma, a definitive description of the role is still evolving.

How the sharing of scientific content with HCPs is shifting in an era of accelerated digitalization.

Medical science liaisons (MSL) in the pharma industry were already at their limit pre-COVID. The challenge for MSLs is to identify the most efficient way to upskill their teams and add digital competencies without overloading them.